Summarized by Masters of Longevity from Longevity Technology.
An article previewing a clinical study report about an endoscopic treatment aimed at reducing weight regain after stopping GLP-1 therapy, inviting readers curious about post-medication obesity management and device-based interventions.
Key Takeaways
- In the modified intention-to-treat population of 308 adults, Revita participants maintained about 80% of prior GLP-1 weight loss at six months versus 67% for sham.
- Least-squares mean weight regain was 5.1% for Revita versus 8.2% for sham, a statistically significant difference (p=0.0023).
- Fractyl reported a dose-dependent effect with ≥20 cm duodenal ablation showing 3.8% mean regain versus 8.2% for sham and holds FDA Breakthrough Device designation.
